MA46546A - Composés thérapeutiques et leurs procédés d'utilisation - Google Patents
Composés thérapeutiques et leurs procédés d'utilisationInfo
- Publication number
- MA46546A MA46546A MA046546A MA46546A MA46546A MA 46546 A MA46546 A MA 46546A MA 046546 A MA046546 A MA 046546A MA 46546 A MA46546 A MA 46546A MA 46546 A MA46546 A MA 46546A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016102263 | 2016-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46546A true MA46546A (fr) | 2021-05-05 |
Family
ID=62018232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046546A MA46546A (fr) | 2016-10-17 | 2017-09-26 | Composés thérapeutiques et leurs procédés d'utilisation |
Country Status (21)
Country | Link |
---|---|
US (2) | US10457654B2 (fr) |
EP (1) | EP3526205A4 (fr) |
JP (1) | JP2019532077A (fr) |
KR (1) | KR20190078587A (fr) |
CN (1) | CN110072855A (fr) |
AR (1) | AR109964A1 (fr) |
AU (1) | AU2017347549A1 (fr) |
BR (1) | BR112019007763A2 (fr) |
CA (1) | CA3039853A1 (fr) |
CL (1) | CL2019001041A1 (fr) |
CO (1) | CO2019004978A2 (fr) |
CR (1) | CR20190236A (fr) |
IL (1) | IL265955A (fr) |
MA (1) | MA46546A (fr) |
MX (1) | MX2019004232A (fr) |
PE (1) | PE20190980A1 (fr) |
PH (1) | PH12019500839A1 (fr) |
RU (1) | RU2019114964A (fr) |
SG (1) | SG11201903348UA (fr) |
TW (1) | TW201821412A (fr) |
WO (1) | WO2018072602A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017091592A1 (fr) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
AR114263A1 (es) * | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
WO2020248123A1 (fr) * | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Composés d'arylsulfonamide substitués par hydroxypyrrolidine ayant une activité sélective dans des canaux sodiques voltage-dépendants |
CN112745279A (zh) * | 2019-10-31 | 2021-05-04 | 杭州澳医保灵药业有限公司 | 醋甲唑胺及其类似物及其在正常压力脑积水的治疗中的应用 |
CN115784922B (zh) * | 2022-11-09 | 2024-03-29 | 苏州爱玛特生物科技有限公司 | 一种(2s)-2-氨基-4-(环丙基/环丁基)丁酸的制备方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
US4130566A (en) | 1977-10-27 | 1978-12-19 | Sumitomo Chemical Company, Limited | Process for producing 5-carboxy-2-acetylthiophene |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
DK24089D0 (da) | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
ATE232529T1 (de) | 1992-11-23 | 2003-02-15 | Aventis Pharma Inc | Substituierte 3-(aminoalkylamino)-1,2- benzisoxazole und verwandte verbindungen |
PL180634B1 (pl) | 1993-11-19 | 2001-03-30 | Parke Davis & Co | Nowe zwiazki, pochodne 5,6-dihydropiranonu i przeciwwirusowy srodek farmaceutyczny PL PL PL PL PL |
US5573653A (en) | 1994-07-11 | 1996-11-12 | Sandoz Ltd. | Electrochemical process for thiocyanating aminobenzene compounds |
AU688102B2 (en) | 1994-08-30 | 1998-03-05 | Sankyo Company Limited | Isoxazoles |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6608105B2 (en) | 2000-12-18 | 2003-08-19 | Meiji Dairies Corporation | TNF-α production inhibitor comprising kavalactone as an active ingredient |
KR100789567B1 (ko) | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
DE10201550A1 (de) | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
WO2004014913A2 (fr) | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Inhibiteurs de la phosphodiesterase 4 |
MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
CN1805943A (zh) | 2003-04-15 | 2006-07-19 | 美国辉瑞有限公司 | 作为PPAR调节剂的α取代羧酸 |
ZA200601942B (en) | 2003-08-08 | 2007-05-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
NZ545710A (en) * | 2003-08-08 | 2010-02-26 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7109332B2 (en) | 2003-10-03 | 2006-09-19 | Portola Pharmaceuticals, Inc. | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
US7081539B2 (en) | 2004-03-25 | 2006-07-25 | Dainippon Sumitomo Pharma Co., Ltd. | One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide |
CN1993335A (zh) | 2004-07-30 | 2007-07-04 | 默克公司 | 代谢型谷氨酸受体的二氢茚酮增效剂 |
EP1786782B1 (fr) | 2004-08-12 | 2010-03-31 | Amgen Inc. | Biaryle-sulfonamides |
US7205296B2 (en) | 2004-09-29 | 2007-04-17 | Portola Pharmaceuticals, Inc. | Substituted 2H-1,3-benzoxazin-4(3H)-ones |
JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
JP2009512659A (ja) | 2005-10-19 | 2009-03-26 | エフ.ホフマン−ラ ロシュ アーゲー | N−フェニルフェニルアセトアミド非ヌクレオシド逆転写酵素阻害剤 |
WO2007062078A2 (fr) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Composes modulant l'activite thrombopoietine et procedes correspondants |
AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
WO2007120647A2 (fr) | 2006-04-11 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension |
WO2008045393A2 (fr) | 2006-10-11 | 2008-04-17 | Amgen Inc. | Composés d'imidazo- et de triazolo-pyridine et leurs procédés d'utilisation |
US20100190787A1 (en) | 2007-01-30 | 2010-07-29 | Srinivas Rao Kasibhatla | Modulators of Mitotic Kinases |
MX2009008338A (es) | 2007-02-05 | 2009-08-12 | Xenon Pharmaceuticals Inc | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. |
CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
AU2008256937A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
CN101679262A (zh) | 2007-06-07 | 2010-03-24 | 安斯泰来制药株式会社 | 吡啶酮化合物 |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
TW200911766A (en) | 2007-07-13 | 2009-03-16 | Astrazeneca Ab | New compounds |
EP2184278A4 (fr) | 2007-08-10 | 2011-08-03 | Nippon Chemiphar Co | Antagoniste de récepteur p2x4 |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
CN102076660B (zh) | 2008-06-23 | 2014-01-08 | 安斯泰来制药有限公司 | 磺胺化合物或其盐 |
WO2010022055A2 (fr) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibiteurs de canaux sodiques sensibles au potentiel |
PT2385938E (pt) | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
SI2464645T1 (sl) | 2009-07-27 | 2017-10-30 | Gilead Sciences, Inc. | Zlite heterociklične spojine kot ionsko kanalni modulatorji |
US8809380B2 (en) | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
CA2774647C (fr) | 2009-09-25 | 2017-03-28 | Astellas Pharma Inc. | Compose amide substitue |
WO2011059042A1 (fr) | 2009-11-12 | 2011-05-19 | 武田薬品工業株式会社 | Composé cyclique aromatique |
WO2011063001A1 (fr) | 2009-11-18 | 2011-05-26 | Concert Pharmaceuticals, Inc. | Promédicaments de niacine et versions deutérisées de ceux-ci |
TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
HUE029012T2 (en) | 2010-02-12 | 2017-02-28 | Nivalis Therapeutics Inc | New S-nitrosoglutathion reductase inhibitors |
WO2011153588A1 (fr) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérase virale |
US20120004714A1 (en) | 2010-06-30 | 2012-01-05 | Ryan Kleve | Lead having coil electrode with preferential bending region |
US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
WO2012004743A1 (fr) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques |
CA2804173C (fr) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Inhibiteurs de nav1.7 de type sulfonamide |
EP2590957B1 (fr) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant |
EP2593427B1 (fr) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Dérivés de sulfonamides comme inhibiteurs du nav1.7 pour le traitement de la douleur |
EP2593432B1 (fr) | 2010-07-12 | 2014-10-22 | Pfizer Limited | Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
EP2593433B1 (fr) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendan |
WO2012007868A2 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Composés chimiques |
JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
MX2013002864A (es) | 2010-09-13 | 2013-08-29 | Novartis Ag | Triazina-oxadiazoles. |
WO2012039657A1 (fr) | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Composé chromane inédit pouvant être utilisé dans le cadre du traitement de la douleur |
US9656959B2 (en) | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
WO2012095781A1 (fr) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Dérivés d'indazole comme inhibiteurs des canaux sodiques |
AU2012212196B2 (en) | 2011-02-02 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
SG193241A1 (en) | 2011-03-25 | 2013-10-30 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
US9079902B2 (en) | 2011-08-17 | 2015-07-14 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
EP2766018A4 (fr) | 2011-10-13 | 2015-02-25 | Univ Case Western Reserve | Composés agonistes de rxr et procédés associés |
AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
JP6014154B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
EP2788332A1 (fr) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
CA2857603C (fr) | 2011-12-15 | 2016-08-02 | Pfizer Limited | Derives de sulfonamide |
EP2800740A1 (fr) | 2012-01-04 | 2014-11-12 | Pfizer Limited | N-aminosulfonylbenzamides |
JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
WO2013122897A1 (fr) * | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
WO2013146969A1 (fr) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | Nouveau dérivé de cyclohexane disubstitué |
WO2013177224A1 (fr) * | 2012-05-22 | 2013-11-28 | Genentech, Inc. | Benzamides n-substitués et leur utilisation dans le traitement de la douleur |
WO2014008458A2 (fr) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | Benzamides n-substitués et leurs procédés d'utilisation |
CN104640843A (zh) | 2012-07-19 | 2015-05-20 | 大日本住友制药株式会社 | 1-(环烷基羰基)脯氨酸衍生物 |
RU2015119635A (ru) | 2012-10-26 | 2016-12-20 | Мерк Шарп И Доум Корп. | Соединения бензоксазолинона с избирательной активностью в потенциал-зависимых натриевых каналах |
EP2911663B1 (fr) | 2012-10-26 | 2020-03-18 | Merck Sharp & Dohme Corp. | Composés indazole sulfonamide n-substitués ayant une activité sélective dans les canaux sodiques potentiel-dépendants |
EP2935257B1 (fr) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Sulfonamides cycliques en tant que bloquants des canaux sodiques |
LT2953931T (lt) | 2013-01-31 | 2017-07-25 | Vertex Pharmaceuticals Incorporated | Piridono amidai kaip natrio kanalų moduliatoriai |
US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
EP2968280A4 (fr) | 2013-03-14 | 2016-08-10 | Genentech Inc | Triazolopyridines substituées et leurs procédés d'utilisation |
ES2663798T3 (es) * | 2013-03-14 | 2018-04-17 | Daiichi Sankyo Company, Limited | Fármaco para enfermedades respiratorias |
BR112015022096A8 (pt) | 2013-03-15 | 2019-11-26 | Chromocell Corp | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
WO2014144545A2 (fr) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Benzoxazoles substitués et leurs procédés d'utilisation |
WO2015051043A1 (fr) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Composés d'acylsulfonamide de biaryle en tant qu'inhibiteurs des canaux sodiques |
PE20161247A1 (es) | 2013-11-27 | 2016-11-30 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas |
WO2015077905A1 (fr) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Composés de benzènesulfonamide à substitution bicycloamine ayant une activité sélective dans les canaux sodiques sensibles à la tension |
CA2986045A1 (fr) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Benzamides substitues et leurs methodes d'utilisation |
CA3003119C (fr) * | 2015-11-13 | 2019-10-22 | Daewoong Pharmaceutical Co., Ltd. | Bloqueur des canaux sodiques |
AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
TN2018000195A1 (en) | 2015-12-18 | 2019-10-04 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
WO2018017896A1 (fr) | 2016-07-20 | 2018-01-25 | Amgen Inc. | Sulfonamides de pyridine |
-
2017
- 2017-09-26 RU RU2019114964A patent/RU2019114964A/ru not_active Application Discontinuation
- 2017-09-26 MA MA046546A patent/MA46546A/fr unknown
- 2017-09-26 CN CN201780077257.9A patent/CN110072855A/zh active Pending
- 2017-09-26 JP JP2019520725A patent/JP2019532077A/ja active Pending
- 2017-09-26 CR CR20190236A patent/CR20190236A/es unknown
- 2017-09-26 MX MX2019004232A patent/MX2019004232A/es unknown
- 2017-09-26 WO PCT/CN2017/103499 patent/WO2018072602A1/fr active Application Filing
- 2017-09-26 EP EP17863182.6A patent/EP3526205A4/fr not_active Withdrawn
- 2017-09-26 AU AU2017347549A patent/AU2017347549A1/en not_active Abandoned
- 2017-09-26 BR BR112019007763A patent/BR112019007763A2/pt not_active IP Right Cessation
- 2017-09-26 KR KR1020197013820A patent/KR20190078587A/ko not_active Application Discontinuation
- 2017-09-26 PE PE2019000843A patent/PE20190980A1/es unknown
- 2017-09-26 SG SG11201903348UA patent/SG11201903348UA/en unknown
- 2017-09-26 CA CA3039853A patent/CA3039853A1/fr not_active Abandoned
- 2017-10-17 AR ARP170102884A patent/AR109964A1/es unknown
- 2017-10-17 TW TW106135501A patent/TW201821412A/zh unknown
- 2017-10-31 US US15/799,771 patent/US10457654B2/en not_active Expired - Fee Related
-
2019
- 2019-04-10 IL IL265955A patent/IL265955A/en unknown
- 2019-04-16 CL CL2019001041A patent/CL2019001041A1/es unknown
- 2019-04-16 PH PH12019500839A patent/PH12019500839A1/en unknown
- 2019-05-15 CO CONC2019/0004978A patent/CO2019004978A2/es unknown
- 2019-09-19 US US16/576,569 patent/US20200115354A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20190980A1 (es) | 2019-07-09 |
CO2019004978A2 (es) | 2019-07-31 |
EP3526205A1 (fr) | 2019-08-21 |
US10457654B2 (en) | 2019-10-29 |
BR112019007763A2 (pt) | 2019-07-02 |
CR20190236A (es) | 2019-09-09 |
EP3526205A4 (fr) | 2020-05-27 |
AU2017347549A1 (en) | 2019-05-02 |
KR20190078587A (ko) | 2019-07-04 |
PH12019500839A1 (en) | 2019-06-24 |
CN110072855A (zh) | 2019-07-30 |
JP2019532077A (ja) | 2019-11-07 |
CL2019001041A1 (es) | 2019-06-21 |
MX2019004232A (es) | 2019-08-01 |
CA3039853A1 (fr) | 2018-04-26 |
US20200115354A1 (en) | 2020-04-16 |
WO2018072602A1 (fr) | 2018-04-26 |
US20180105504A1 (en) | 2018-04-19 |
TW201821412A (zh) | 2018-06-16 |
AR109964A1 (es) | 2019-02-06 |
RU2019114964A3 (fr) | 2021-01-29 |
RU2019114964A (ru) | 2020-11-17 |
IL265955A (en) | 2019-05-30 |
SG11201903348UA (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA40069A (fr) | Molécules de liaison trispécifiques et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA41951A (fr) | Gènes insecticides et procédés d'utilisation | |
MA39915B1 (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation |